Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome.

[1]  K. Furie,et al.  Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2007, Circulation.

[2]  J. J. Griffin,et al.  Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction--the smoker's paradox revisited. , 2005, American heart journal.

[3]  M. Hori,et al.  Impact of smoking status on long-term mortality in patients with acute myocardial infarction. , 2005, Circulation journal : official journal of the Japanese Circulation Society.

[4]  Deepak L. Bhatt,et al.  Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. , 2005, JAMA.

[5]  H. Brenner,et al.  Short-term benefit of smoking cessation in patients with coronary heart disease: estimates based on self-reported smoking data and serum cotinine measurements. , 2004, European heart journal.

[6]  Deepak L. Bhatt,et al.  Utilization of Early Invasive Management Strategies for High-Risk Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: Results From the CRUSADE Quality Improvement Initiative , 2004 .

[7]  V. McCormack,et al.  Issues in the reporting of epidemiological studies: a survey of recent practice , 2004, BMJ : British Medical Journal.

[8]  R. Califf,et al.  Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library. , 2004, American heart journal.

[9]  R. Califf,et al.  Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. , 2004, JAMA.

[10]  F. G. Gómez Jiménez,et al.  Paradoxical effect of smoking in the Spanish population with acute myocardial infarction or unstable angina: results of the ARIAM Register. , 2004, Chest.

[11]  J. Critchley,et al.  Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. , 2003, JAMA.

[12]  P. Armstrong,et al.  Randomized Evaluation of the Safety and Efficacy of Enoxaparin Versus Unfractionated Heparin in High-Risk Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Receiving the Glycoprotein IIb/IIIa Inhibitor Eptifibatide , 2003 .

[13]  Carl J Pepine,et al.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.

[14]  GlYcoprotein IIb,et al.  The SYNERGY trial: study design and rationale. , 2002, American heart journal.

[15]  H. Barron,et al.  Smoking and mortality following acute myocardial infarction: results from the National Registry of Myocardial Infarction 2 (NRMI 2). , 2002, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[16]  R. Califf,et al.  Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigators. , 2000, American heart journal.

[17]  E. Antman,et al.  Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. , 1999, Circulation.

[18]  L. Wallentin,et al.  Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study , 1999, The Lancet.

[19]  S. Goto,et al.  Platelet spontaneous aggregation in platelet-rich plasma is increased in habitual smokers. , 1999, Thrombosis research.

[20]  A. Siegbahn,et al.  Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary artery disease. , 1999, American heart journal.

[21]  A. Siegbahn,et al.  Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators. , 1999, Lancet.

[22]  J. Weitz.  Low-molecular-weight heparins. , 1997, The New England journal of medicine.

[23]  D. Waters,et al.  Effects of Cigarette Smoking on the Angiographic Evolution of Coronary Atherosclerosis: A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy , 1996 .

[24]  D. Waters,et al.  Effects of cigarette smoking on the angiographic evolution of coronary atherosclerosis. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy. CCAIT Study Group. , 1996, Circulation.

[25]  R. Califf,et al.  Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the "smoker's paradox" from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded , 1995, Journal of the American College of Cardiology.

[26]  M. Winniford,et al.  Coronary-artery vasoconstriction induced by cocaine, cigarette smoking, or both. , 1994, The New England journal of medicine.

[27]  M. Woodward,et al.  Biochemical evidence of persistent heavy smoking after a coronary diagnosis despite self-reported reduction: analysis from the Scottish Heart Health Study. , 1992, European heart journal.

[28]  A. Folsom,et al.  Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. , 1991, Atherosclerosis.

[29]  J. Wittes,et al.  Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. , 1991, JAMA.

[30]  C. Taylor,et al.  Smoking cessation after acute myocardial infarction: effects of a nurse-managed intervention. , 1990, Annals of internal medicine.

[31]  R. Luepker,et al.  Validity of telephone surveys in assessing cigarette smoking in young adults. , 1989, American journal of public health.